The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer

Their antiangiogenic effects make vascular endothelial growth factor receptor 2 (VEGFR2/KDR/Flk-1) inhibitors useful for Cancer treatment. However, most of these drugs have unexpected adverse side effects. Here, we show that the novel VEGFR2/KDR/Flk-1 inhibitor YLL545 suppressed tumor angiogenesis and growth in triple-negative breast Cancer without adverse effects. YLL545 treatment also markedly inhibited proliferation, migration, invasion, and tube formation by human umbilical vascular endothelial cells (HUVECs) in vitro. These effects of YLL545 were equal to or greater than those seen with sorafenib. In addition, YLL545 inhibited VEGF-induced phosphorylation of VEGFR2/KDR/Flk-1 and activation of downstream signaling regulators, such as phospho-STAT3 and phospho-ERK1/2, in HUVECs. Embryonic angiogenesis assays in zebrafish and Matrigel plug assays in mice demonstrated that YLL545 inhibits angiogenesis in vivo. YLL545 also inhibited proliferation and induced Apoptosis in MDA-MB-231 breast Cancer cells both in vitro and in vivo, and 50 mg/kg/d YLL545 inhibited human tumor xenograft growth by more than 50% in BALB/c nude mice. These observations suggest YLL545 is a potentially useful Anticancer drug candidate.

VEGFR2 inhibitor; angiogenesis; breast cancer; tumor gowth.